Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015 May;16(5):522-30 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/25840693.
Compare quality appraisals for each clinical question
- What is the appropriate treatment of macroscopic (i.e. detectable clinically or by ultrasound) nodal metastases?
- What is the role of adjuvant systemic therapy in patients with resected stage II and stage III melanoma?